Primary Peritoneal Clear Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: An extremely rare adenocarcinoma arising from the peritoneum. It is composed of malignant glandular epithelium containing clear cells. 
There are 13 clinical trials for primary peritoneal clear cell carcinoma, of which 12 are open and 1 is completed or closed. Of the trials that contain primary peritoneal clear cell carcinoma as an inclusion criterion, 2 are phase 1 (2 open), 5 are phase 1/phase 2 (4 open), 5 are phase 2 (5 open), and 1 is phase 3 (1 open).
BRCA1, BRCA2, and ARID1A are the most frequent gene inclusion criteria for primary peritoneal clear cell carcinoma clinical trials .
Paclitaxel, carboplatin, and avb-s6-500 are the most common interventions in primary peritoneal clear cell carcinoma clinical trials.
Significant Genes in Primary Peritoneal Clear Cell Carcinoma
POLE is an inclusion eligibility criterion in 1 clinical trial for primary peritoneal clear cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and primary peritoneal clear cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.